UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Blood cancer journal (New York), 2021-02, Vol.11 (2), p.19-19, Article 19

2021

Link zum Volltext

Verfügbarkeit prüfen

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report

Journal of cellular and molecular medicine, 2023-01, Vol.27 (2), p.299-303

2023

Link zum Volltext

Verfügbarkeit prüfen

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Blood cancer journal (New York), 2024-05, Vol.14 (1), p.87-9, Article 87

2024

Link zum Volltext

Verfügbarkeit prüfen

Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement

Polskie archiwum medycyny wewne̦trznej, 2021-04, Vol.131 (4), p.361-368

2021

Link zum Volltext

Verfügbarkeit prüfen

T-cell exhaustion in multiple myeloma

Expert review of hematology, 2024-07, Vol.17 (7), p.295-312

2024

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood, 2020-11, Vol.136 (22), p.2513-2523

2020

Link zum Volltext

Verfügbarkeit prüfen

G6PD deficiency—does it alter the course of COVID-19 infections?

Annals of hematology, 2023-07, Vol.102 (7), p.1629-1636

2023

Link zum Volltext

Verfügbarkeit prüfen

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8513-8513

2020

Link zum Volltext

Verfügbarkeit prüfen

ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8001-8001

2022

Link zum Volltext

Verfügbarkeit prüfen

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial

British journal of haematology, 2023-12, Vol.203 (5), p.792-802

2023

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response

American journal of cancer research, 2022-01, Vol.12 (7), p.3280-3293

2022

Link zum Volltext

Verfügbarkeit prüfen

P-397 Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S259-S260

2023

Link zum Volltext

Verfügbarkeit prüfen

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

Leukemia & lymphoma, 2017-09, Vol.58 (9), p.2089-2100

2017

Link zum Volltext

Verfügbarkeit prüfen

OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S6

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

Postȩpy higieny i medycyny doświadczalnej, 2017-01, Vol.71, p.40-46

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

Postȩpy higieny i medycyny doświadczalnej, 2017-01, Vol.71, p.40-46

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Polskie archiwum medycyny wewne̦trznej, 2017-06, Vol.127 (6), p.392-400

2017

Link zum Volltext

Verfügbarkeit prüfen

On cytologic vagaries in the diagnosis of breast tumors

Tumori, 1980-04, Vol.66 (2), p.191

1980

Link zum Volltext

Verfügbarkeit prüfen

Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk—Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13178

2023

Link zum Volltext

Verfügbarkeit prüfen

Trityl-Based Lanthanide-Supramolecular Assemblies Exhibiting Slow Magnetic Relaxation

Chemistry : a European journal, 2023-09, Vol.29 (53), p.e202300695-e202300695

2023

Link zum Volltext

Verfügbarkeit prüfen

Preliminary studies on LTCC based PCR microreactor

Sensors and actuators. B, Chemical, 2010-10, Vol.150 (2), p.715-721

2010

Link zum Volltext

Verfügbarkeit prüfen

Highly selective synthesis of ( E)- N-aryl- N-(1-propenyl) ethanamides via isomerization of N-allyl ethanamides catalyzed by ruthenium complexes

Tetrahedron letters, 2001-10, Vol.42 (40), p.7095-7098

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(15)
Humans
(11)
Oncology
(8)
Hematology
(7)
Multiple Myeloma
(7)
Chemistry
(6)
Female
(6)
Physical Sciences
(6)
Aged
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Middle Aged
(5)
Multiple Myeloma - Drug Therapy
(5)
Dexamethasone - Administration & Dosage
(4)
Dexamethasone - Therapeutic Use
(4)
Male
(4)
Adult
(3)
Lenalidomide - Therapeutic Use
(3)
Multiple Myeloma - Diagnosis
(3)
Multiple Myeloma - Mortality
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement

T-cell exhaustion in multiple myeloma

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

G6PD deficiency—does it alter the course of COVID-19 infections?

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial

Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

P-397 Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

On cytologic vagaries in the diagnosis of breast tumors

Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk—Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland

Trityl-Based Lanthanide-Supramolecular Assemblies Exhibiting Slow Magnetic Relaxation

Preliminary studies on LTCC based PCR microreactor

Highly selective synthesis of ( E)- N-aryl- N-(1-propenyl) ethanamides via isomerization of N-allyl ethanamides catalyzed by ruthenium complexes

Suchergebnisse filtern